

CLAIMS

1. A pharmaceutical composition comprising a statin and
an antifatulent agent in a suitable proportion as
active ingredient.
2. A pharmaceutical composition according to claim 1
wherein the statin is selected from the group
consisting of atorvastatin, cerivastatin, fluvastatin,
lovastatin, pitavastatin, pravastatin, rosuvastatin
and simvastatin, and pharmaceutically acceptable salts
and hydrates thereof.
3. A pharmaceutical composition according to claim 2
wherein the statin is simvastatin or a
pharmaceutically acceptable salt thereof.
4. A pharmaceutical composition according to any one of
claims 1 to 3 wherein the antifatulent agent is
selected from the group consisting of simethicone and
dimethicone.
5. A pharmaceutical composition according to claim 4
wherein the antifatulent agent is simethicone.
6. A pharmaceutical composition according to any one of
the preceding claims wherein the composition is a
tablet, capsule, syrup, solution, powder, granule, or
emulsion.
7. A pharmaceutical composition according to claim 6
wherein the tablet is a coated tablet.

8. A pharmaceutical composition according to claim 7 wherein the coated tablet comprises a core and a coating, the core comprising the statin and the antiflatulent agent.

5

9. A pharmaceutical composition according to any one of the preceding claims, wherein the weight ratio of antiflatulent agent versus statin is at least 0.25.

10

10. A pharmaceutical composition according to any one of the preceding claims, wherein the weight ratio of antiflatulent agent versus statin is at least 1,50.

15

11. A pharmaceutical composition according to claim 6 or 7 wherein simvastatin is present in an amount from 2.5 to 100 mg per tablet.

20

12. A pharmaceutical composition according to claim 11 wherein simvastatin is present in an amount from 5 to 80 mg per tablet.

25

13. A pharmaceutical composition according to claims 6 or 7 wherein simethicone is present in an amount from 25 to 250 mg per tablet.

30

14. A pharmaceutical composition according to claim 13 wherein simethicone is present in an amount of 125 mg per tablet.

15. A pharmaceutical composition according to any one of the preceding claims further comprising one or more diluents, one or more binders, one or more disintegrants and one or more lubricants.

16. A pharmaceutical composition according to claim 15
wherein the diluent is selected from the group
consisting of microcrystalline celluloses and their
5 derivatives, lactose, mannitol, calcium phosphates,
starch, and the mixtures thereof.
17. A pharmaceutical composition according to claim 15
wherein the binder is selected from the group
10 consisting of starch, polyethylene glycols,
polyvinylpyrrolidones, cellulose derivatives, and the
mixtures thereof.
18. A pharmaceutical composition according to claim 15
15 wherein the disintegrant is selected from the group
consisting of colloidal silicon dioxide,
croscarmellose, la polyvinylpyrrolidone, starch and
its pregelatinized derivatives, and the mixtures
thereof.
- 20 19. A pharmaceutical composition according to claim 15
wherein the lubricant is selected from the group
consisting of talc, magnesium stearate, stearic acid,
sodium stearyl fumarate, PEG 8000, and the mixtures
25 thereof.
20. A pharmaceutical composition according to any one of
the preceding claims further comprising one or more
antioxidants and one or more wetting agents.
- 30 21. A pharmaceutical composition according to claim 7
wherein the coating of the tablet comprises a
cellulose derivative or its pharmaceutically

acceptable salt, an acrylic polymer, triethyl citrate, titanium dioxide and one or more lubricants.

22. A pharmaceutical composition according to claim 21
5 wherein the cellulose derivative is hydroxypropyl methylcellulose.

23. A pharmaceutical composition according to any one of
the preceding claims further comprising one or more
10 colouring agents.

24. A process for preparing a pharmaceutical composition
according to any one of the preceding claims by direct
compression of components thereof.
15